Umb Bank, N.A. Bristol Myers Squibb CO Transaction History

Umb Bank, N.A.

$6.22 Billion
Q4 2024

A detailed history of Umb Bank, N.A. transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Umb Bank, N.A. holds 205,457 shares of BMY stock, worth $11.8 Million. This represents 0.19% of its overall portfolio holdings.

Number of Shares

205,457

Previous 73,862 178.16%

Holding current value

$11.8 Million

Previous $3.82 Million 204.03%

% of portfolio

0.19%

Previous 0.06%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Jan 16, 2025	BUY	$51.92 - $59.94 $6.83 Million - $7.89 Million	131,595 Added 178.16%	205,457 $11.6 Million
Q3 2024 Oct 08, 2024	SELL	$39.66 - $51.75 $395,846 - $516,516	-9,981 Reduced 11.9%	73,862 $3.82 Million
Q2 2024 Jul 29, 2024	SELL	$40.25 - $52.99 $791,596 - $1.04 Million	-19,667 Reduced 19.0%	83,843 $3.48 Million
Q1 2024 Apr 26, 2024	SELL	$47.98 - $54.4 $597,734 - $677,715	-12,458 Reduced 10.74%	103,510 $5.61 Million
Q4 2023 Jan 23, 2024	SELL	$48.48 - $57.85 $1.05 Million - $1.25 Million	-21,688 Reduced 15.76%	115,968 $5.95 Million
Q3 2023 Oct 18, 2023	SELL	$57.89 - $64.73 $305,138 - $341,191	-5,271 Reduced 3.69%	137,656 $7.99 Million
Q2 2023 Jul 25, 2023	SELL	$63.71 - $70.74 $235,217 - $261,172	-3,692 Reduced 2.52%	142,927 $9.14 Million
Q1 2023 Apr 11, 2023	SELL	$65.71 - $74.53 $112,101 - $127,148	-1,706 Reduced 1.15%	146,619 $10.2 Million
Q4 2022 Jan 10, 2023	SELL	$68.48 - $81.09 $379,995 - $449,968	-5,549 Reduced 3.61%	148,325 $10.7 Million
Q3 2022 Oct 13, 2022	SELL	$0.13 - $76.84 $1,075 - $635,927	-8,276 Reduced 5.1%	153,874 $10.9 Million
Q2 2022 Jul 20, 2022	SELL	$72.62 - $79.98 $307,037 - $338,155	-4,228 Reduced 2.54%	162,150 $12.5 Million
Q1 2022 Apr 22, 2022	BUY	$61.48 - $73.72 $162,184 - $194,473	2,638 Added 1.61%	166,378 $12.2 Million
Q4 2021 Feb 09, 2022	BUY	$53.63 - $62.52 $1.37 Million - $1.59 Million	25,488 Added 18.44%	163,740 $10.2 Million
Q3 2021 Oct 18, 2021	BUY	$59.17 - $69.31 $62,897 - $73,676	1,063 Added 0.77%	138,252 $8.18 Million
Q2 2021 Jul 26, 2021	SELL	$61.91 - $67.42 $40,798 - $44,429	-659 Reduced 0.48%	137,189 $9.17 Million
Q1 2021 Apr 15, 2021	SELL	$59.34 - $66.74 $104,319 - $117,328	-1,758 Reduced 1.26%	137,848 $8.7 Million
Q4 2020 Feb 04, 2021	SELL	$57.74 - $65.43 $872,335 - $988,516	-15,108 Reduced 9.77%	139,606 $8.66 Million
Q2 2020 Jul 16, 2020	SELL	$54.82 - $64.09 $254,803 - $297,890	-4,648 Reduced 2.92%	154,714 $9.1 Million
Q1 2020 May 26, 2020	BUY	$46.4 - $67.43 $79,158 - $115,035	1,706 Added 1.08%	159,362 $8.88 Million
Q4 2019 Jan 31, 2020	BUY	$49.21 - $64.19 $799,022 - $1.04 Million	16,237 Added 11.48%	157,656 $10.1 Million
Q3 2019 Oct 30, 2019	BUY	$42.77 - $50.71 $1.07 Million - $1.26 Million	24,920 Added 21.39%	141,419 $7.17 Million
Q2 2019 Jul 30, 2019	BUY	$44.62 - $49.34 $1.63 Million - $1.81 Million	36,610 Added 45.83%	116,499 $5.28 Million
Q1 2019 Apr 30, 2019	SELL	$45.12 - $53.8 $280,375 - $334,313	-6,214 Reduced 7.22%	79,889 $3.81 Million
Q4 2018 Jan 24, 2019	SELL	$48.76 - $63.23 $36,765 - $47,675	-754 Reduced 0.87%	86,103 $4.48 Million
Q3 2018 Oct 22, 2018	SELL	$55.19 - $62.25 $67,828 - $76,505	-1,229 Reduced 1.4%	86,857 $5.39 Million
Q2 2018 Jul 31, 2018	SELL	$50.53 - $62.98 $1.22 Million - $1.52 Million	-24,139 Reduced 21.51%	88,086 $4.88 Million
Q1 2018 Apr 25, 2018	SELL	$59.92 - $68.98 $1.14 Million - $1.31 Million	-19,032 Reduced 14.5%	112,225 $7.1 Million
Q4 2017 Jan 22, 2018	SELL	$59.94 - $65.35 $110,409 - $120,374	-1,842 Reduced 1.38%	131,257 $8.04 Million
Q3 2017 Oct 11, 2017	BUY	$55.23 - $63.74 $7.35 Million - $8.48 Million	133,099	133,099 $8.48 Million

Others Institutions Holding BMY

# of Institutions

2,632

Shares Held

1.47B

Call Options Held

31.5M

Put Options Held

34.9M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $122B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Umb Bank, N.A., based on Form 13F filings with the SEC.

News

Stay updated on Umb Bank, N.A. with notifications on news.

Account